SLC5A2 and diabetic kidney disease: In the diabetic kidney disease models, SGLT2 inhibitors like dapagliflozin, empagliflozin, and canagliflozin have shown significant anti-inflammatory, anti-oxidative, and anti-fibrotic properties.